Tesamorelin
Also known as: TH 9507 · tesamorelina · tesamoreline · tesamorelinum
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog and an FDA-approved prescription drug (marketed as Egrifta). Material sold as a research peptide is offered for laboratory and research use only and is not the approved pharmaceutical product. It is studied in research for visceral-fat reduction.
What is Tesamorelin?
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analog. Tesamorelin functions as a growth hormone secretagogue that activates the growth hormone-releasing hormone (GHRH) receptor, leading to increased secretion of growth hormone. This elevation in growth hormone subsequently stimulates insulin-like growth factor 1 (IGF-1) signaling pathways, which are involved in tissue repair and cellular regeneration.
It is best referenced by its chemistry (PubChem CID 16137828, molecular formula C221H366N72O67S). Tesamorelin is sold and discussed for laboratory and research use only, separate from its approved pharmaceutical form.
Key Benefits & Mechanisms
Mechanism of action
Tesamorelin functions as a growth hormone secretagogue that activates the growth hormone-releasing hormone (GHRH) receptor, leading to increased secretion of growth hormone. This elevation in growth hormone subsequently stimulates insulin-like growth factor 1 (IGF-1) signaling pathways, which are involved in tissue repair and cellular regeneration.
Research Summary
Tesamorelin has been examined in peer-reviewed research; representative studies are listed below. The publicly available evidence is primarily preclinical, and Tesamorelin is an approved drug only in its pharmaceutical form — research-grade material remains research-use-only.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026) PubMed · PMID 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (2026) PubMed · PMID 41476424
Frequently asked questions about Tesamorelin
Is Tesamorelin FDA approved?
Tesamorelin is an FDA-approved prescription drug (marketed as Egrifta). However, material sold online as a research peptide is not the approved pharmaceutical product and is for research use only.
What is Tesamorelin studied for?
In research, Tesamorelin is studied for visceral-fat reduction. Tesamorelin functions as a growth hormone secretagogue that activates the growth hormone-releasing hormone (GHRH) receptor, leading to increased secretion of growth hormone. This elevation in growth hormone subsequently stimulates insulin-like growth factor 1 (IGF-1) signaling pathways, which are involved in tissue repair and cellular regeneration.
How is Tesamorelin stored?
Like most peptides, lyophilized Tesamorelin is best kept cold, dark, and dry; reconstituted material is refrigerated and used within a limited window. See the storage and reconstitution guide for details.
Legal & research status: Tesamorelin is an FDA-approved prescription drug (marketed as Egrifta). Material sold as a research peptide is not the approved pharmaceutical product and is offered for laboratory and research use only, not for human consumption.